ERBB2 and breast carcinoma: ERBB2 amplified tumors are matched to anti-HER2 antibody, trastuzumab, treatment and are classified as tier I-A in breast cancer and are currently investigated in multiple clinical trials in OC patients (e.g. DESTINY: phase 2.